NCT07660640

Brief Summary

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Trial Health

78
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for all trials

Timeline
62mo left

Started Mar 2026

Longer than P75 for all trials

Geographic Reach
2 countries

4 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Mar 2026Aug 2031

Study Start

First participant enrolled

March 3, 2026

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 16, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 22, 2026

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2031

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2031

Last Updated

June 22, 2026

Status Verified

February 1, 2026

Enrollment Period

5.4 years

First QC Date

June 16, 2026

Last Update Submit

June 16, 2026

Conditions

Age-Related Macular Degeneration (AMD)Non-Neovascular Age-Related Macular Degeneration

Keywords

Long term follow up, extension study

Outcome Measures

Primary Outcomes (1)

  • Frequency of ocular and systemic VOY-101 related AEs

    Frequency of ocular and systemic VOY-101 related AEs (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\]).

    3 years

Study Arms (1)

Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

Long-term safety extension from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

Other: observational studyBiological: VOY-101

Interventions

observational studyOTHER

No intervention - observational study

Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
VOY-101BIOLOGICAL

One-time intravitreal injection of VOY-101.

Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

You may qualify if:

  • Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101.
  • Are willing and able to understand and provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Ophthalmic Consultants of Boston

Boston, Massachusetts, 02114, United States

Location

Retina Consultants of Texas

Bellaire, Texas, 77401, United States

Location

University of Utah

Salt Lake City, Utah, 84132, United States

Location

Sourasky Medical Center - Ichilov

Tel Aviv, 6423906, Israel

Location

MeSH Terms

Conditions

Macular Degeneration

Interventions

Observation

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 16, 2026

First Posted

June 22, 2026

Study Start

March 3, 2026

Primary Completion (Estimated)

July 30, 2031

Study Completion (Estimated)

August 30, 2031

Last Updated

June 22, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

US(3)IL(1)